"I’ve been using Affimer technology in my research for the past year and the data generated has been remarkable. My interest lies in understanding the mechanisms for blood clot formation and breakdown with the long-term aim of reducing heart attacks and strokes in high risk patients. A number of Affimer candidates have shown significant effects on the clotting process, which will help to develop novel therapeutic targets aiming to reduce thrombosis risk."
Dr Ramzi Ajjan
Associate Professor / Consultant, Diabetes and Endocrinology, University of Leeds and Leeds NHS Trust
Watch our interview with Dr Ramzi Ajjan, below.
"Our research interests lie in studying the function of FcgRs in autoimmune and inflammatory diseases. The Affimer candidates we’ve isolated have shown remarkable specificity and have proved useful not only as detection tools, but also for blocking receptor function. Furthermore, crystallisation of Affimer molecules with the receptors have identified allosteric inhibitors. Overall we’re delighted with the results and hope to develop them into therapeutics."
Professor Ann W Morgan
Hon. Consultant Rheumatologist, University of Leeds
To find out more about Professor Morgan's work with Affimer technology, download our poster: ' Allosteric inhibition of FcgRIIIa-IgG interactions using Affimer technology'
"Affimer technology provides a unique opportunity for the development of diagnostic devices. Its high affinity, robustness, ease of use and bespoke modifications for simple surface attachment make it an ideal candidate for high-throughput biosensor arrays. We started using Affimer technology on electrical and electrochemical biosensors with great success. It is now in fact playing a critical role in several projects within the Marie Curie Initial Training Network PROSENSE."
Dr Pedro Estrela - Senior Lecturer
Dept. of Electronic and Electrical Engineering, University of Bath
"My laboratory studies SUMO-dependent protein-protein interactions (PPIs), which is complicated by the existence of several, highly similar isoforms of SUMO. We turned to Affimer technology to develop isoform-specific inhibitors of SUMO-PPIs, which has transformed our ability to understand these essential cellular processes. Very rapidly, we were able to generate a range of reagents that we've used in vitro, in cell-based assays and in X-ray crystallography studies to gain an understanding of SUMO-PPIs at the atomic level."
Dr David Hughes
Research Fellow, University of St.Andrews, School of Biology
To find out more about Dr Hughes' work with Affimer technology, download our poster: ' Isoform specific inhibition of human SUMO proteins using Affimer technology '.
"We use Affimer technology in a synthetic biology approach to design disease resistance in plants, focussing on the powdery mildew fungus. Using Affimer reagents to target virulence components, we have been able to obtain very promising results that may allow us to take this serious pathogen out of the game."
Professor Hans Thordal-Christensen
Dept. of Plant and Environmental Sciences, University of Copenhagen
To find out more about Professor Thordal-Christensen's work with Affimer technology, read the case study 'Engineering plant disease resistance with Affimer technology'
"We have been able to demonstrate effective label free electrochemical immunoassays within which performance exceeds that associated with comparable antibodies."
Professor Jason J Davis
Dept. of Chemistry, Christ Church College, University of Oxford